IDH1 and acute myeloid leukemia: Ivosidenib and enasidenib are two oral drugs which inhibit IDH1 and IDH2 mutated proteins, respectively; these drugs are indicated as monotherapy for R/R IDH1 and IDH2-mutated AML cases.